Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bush Rx discount card

Executive Summary

House Small Business Committee is understood to have tentatively scheduled a hearing for mid-September on the effect President Bush's prescription drug discount card plan would have on pharmacies. During a July 25 Small Business Committee hearing on reducing regulatory burdens on small healthcare providers, Ranking Democrat Velazquez (N.Y.) asked Centers for Medicare & Medicaid Services Administrator Tom Scully to provide a report on the discount card's impact. National Community Pharmacists Association and the National Association of Chain Drug Stores filed for a preliminary court injunction against the program July 26 (1"The Pink Sheet" July 23, p. 5)

You may also be interested in...



Bush Rx Card Plan Would Not Require PBMs To Report, Share Rebates

The Bush Administration's Medicare prescription discount card plan would not require participating prescription benefit programs to report rebates to the government or pass on savings to beneficiaries.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

PS038242

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel